Emergent BioSolutions Inc. (NYSE: EBS) announced today that two abstracts on its humanized anti-CD37 mono-specific protein therapeutic, otlertuzumab (TRU-016), being evaluated in patients with chronic lymphocytic leukemia (CLL), have been accepted for presentation at the 55th Annual Meeting of the American Society of Hematology (ASH) on December 7-10, 2013 in New Orleans, Louisiana. The abstracts are available on the ASH website at www.hematology.org.
Help employers find you! Check out all the jobs and post your resume.
